BioXcel Therapeutics, Inc. (BTAIQ) Operating income 2017–2025
BioXcel Therapeutics, Inc. (BTAIQ) annual operating income history from SEC filings — each fiscal year as reported.
-$50.5MFY2025 · since FY2017: -$4.5M → -$50.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$50.5M | +25.0% |
| FY2024 | -$67.2M | +60.9% |
| FY2023 | -$171.8M | -7.6% |
| FY2022 | -$159.6M | -49.3% |
| FY2021 | -$106.9M | -29.9% |
| FY2020 | -$82.3M | -144.9% |
| FY2019 | -$33.6M | -68.3% |
| FY2018 | -$20.0M | -340.0% |
| FY2017 | -$4.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BTAIQ financial trends
BTAIQ RevenueBTAIQ Net incomeBTAIQ Net marginBTAIQ Gross profitBTAIQ Gross marginBTAIQ Operating marginBTAIQ Operating cash flowBTAIQ Free cash flowBTAIQ Capital expendituresBTAIQ Return on equityBTAIQ Stock buybacksBTAIQ Dividends paidBTAIQ Total assetsBTAIQ Total liabilitiesBTAIQ Shareholders’ equityBTAIQ overview →